FDA concurred with its Advisory Committee’s recommendations and has turned down Depomed’s application seeking a new indication for gabapentin.  Depomed has sought approval to use the drug in the treatment of menopausal symptoms – ‘hot flashes’. We reviewed the Advisory Committee’s deliberations in this blog this past April.  The drug failed to show superiority over placebo.  Depomed issued a press release confirming the news and indicated it would cease all further development efforts for this indication.